Virtually all rodent neuroendocrine corticotropin-releasing-hormone (CRH) neurons are in the dorsal medial parvicellular (mpd) part of the paraventricular nucleus of the hypothalamus (PVH). They form the final common pathway for adrenocortical stress responses. Their activity is controlled by sets of GABA-, glutamate-, and catecholamine-containing inputs arranged in an interactive premotor network. Defining the nature and arrangement of these inputs can help clarify how stressor type and intensity information is conveyed to neuroendocrine neurons. Here we use immunohistochemistry with high-resolution 3-dimensional image analyses to examine the arrangement of single-and co-occurring GABA, glutamate, and catecholamine markers in synaptophysin-defined pre-synaptic terminals in the PVHmpd of unstressed rats and Crh-IRES-Cre;Ai14 transgenic mice: respectively, vesicular glutamate transporter 2 (VGluT2), vesicular GABA transporter (VGAT), dopamine b-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT). Just over half of all PVHmpd pre-synaptic terminals contain VGAT, with slightly less containing VGluT2. The vast majority of terminal appositions with mouse CRH neurons occur non-somatically. However, there are significantly more somatic VGAT than VGluT2 appositions. In the rat PVHmpd, about five times as many pre-synaptic terminals contain PNMT than DBH only. However, because epinephrine release has never been detected in the PVH, PNMT terminals may functionally be noradrenergic not adrenergic. PNMT and VGluT2 co-occur in some pre-synaptic terminals indicating the potential for co-transmission of glutamate and norepinephrine. Collectively, these results provide a structural basis for how GABA/glutamate/catecholamine interactions enable adrenocortical responses to fast-onset interosensory stimuli, and more broadly, how combinations of PVH neurotransmitters and neuromodulators interact dynamically to control adrenocortical activity.
CRH neurons are controlled by a complex pre-motor network that uses multiple transmitters and peptidergic modulators to relay information from various parts of the brain to the PVHmpd Sawchenko et al., 1985; Herman & Cullinan, 1997; Herman, Tasker, Ziegler, & Cullinan, 2002; Herman, et al., 2003; Watts, 2005; Bains, Wamsteeker Cusulin, & Inoue, 2015) . Substantial evidence supports key roles for GABA and glutamate as primary controllers of neuroendocrine neurons (Boudaba, Szabo, & Tasker, 1996; Boudaba et al., 1997; Herman et al., 2002; Herman et al., 2004; Kuzmiski et al., 2010; Inoue et al., 2013) . At least half of the pre-synaptic terminals in the medial hypothalamus are GABAergic (Decavel & van den Pol, 1992) . CRH neurons receive direct GABAergic synaptic innervation (Mikl os & Kov acs, 2002; Flak, Ostrander, Tasker, & Herman, 2009) , and GABA-mediated inhibition is a crucial control element for these neurons (Cole & Sawchenko, 2002; Bali & Kov acs, 2003; Wamsteeker & Bains, 2010; Bains et al., 2015) .
Tonic activation of GABA A receptors inhibits neuroendocrine CRH activity, while blocking these receptors is sufficient to activate the HPA axis (Cole & Sawchenko, 2002) . In this way, neuroendocrine responses to stressors are dependent on GABA receptor mediated control of Cl 2 homeostasis (Hewitt, Wamsteeker, Kurz, & Bains, 2009; Sarkar, Wakefield, MacKenzie, Moss, & Maguire, 2011) . Similarly, numerous glutamate synapses are found within the PVH (Ziegler & Herman, 2000) , and glutamate-containing pre-synaptic terminals appose CRH neurons (Wittmann, Lechan, Liposits, & Fekete, 2005) . Glutamatergic signaling activates the HPA axis (Ziegler & Herman, 2000; Bains et al., 2015) .
A third set of inputs in the neuroendocrine pre-motor network are from hindbrain catecholamine neurons that innervate all subdivisions of the PVH (Swanson et al., 1981; Sawchenko & Swanson, 1982 Liposits, Phelix, & Paull, 1986b; Cunningham & Sawchenko, 1988; Cunningham, Bohn, & Sawchenko, 1990) . They are defined by the presence or absence of three biosynthetic enzymes: tyrosine hydroxylase (TH), dopamine b-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT) (Swanson et al., 1981) . PNMT-containing fibers predominate in the parvicellular PVH, with greatest innervation of the PVHmpd (Swanson et al., 1981; Cunningham et al., 1990) , while the DBH-only innervation is mostly confined to the periventricular and magnocellular PVH (Swanson et al., 1981; Sawchenko & Swanson, 1982) . Catecholaminergic pre-synaptic terminals appose both magno-and parvicellular PVH neurons (Liposits, Phelix, & Paull, 1986a) , including neuroendocrine CRH neurons (Liposits et al., 1986b) .
Catecholaminergic afferents provide stimulus-specific information to the PVHmpd, particularly for acute physiological challenges (Ritter, Li, Wang, & Dinh, 2011; Guyenet et al., 2013) . These neurons are indispensable for glucocorticoid responses to insulin-induced hypoglycemia, and are major contributors for responses to 2-deoxy-D-glucose (2DG) or GLP-1 agonists (Ritter, Bugarith, & Dinh, 2001; Ritter, Watts, Dinh, Sanchez-Watts, & Pedrow, 2003; Khan et al., 2007; Lee et al., 2016) .
They are also required to maintain the sensitivity of CRH mRNA to elevated levels of corticosterone (Kaminski & Watts, 2012) and to gate metaplasticity at GABA inputs on CRH neurons following an acute stress (Inoue et al, 2013) . However, they are not required for the daily rhythms of corticosterone secretion, or for neuroendocrine responses to psychogenic and other complex stressors (Ritter et al., 2003; Khan et al., 2011; Flak et al., 2014) .
PVHmpd afferent systems are highly interactive (Herman et al., 2002 (Herman et al., , 2003 Watts & Sanchez-Watts, 2002; Watts, 2005; Yang et al., 2007 Yang et al., , 2008 Wamsteeker & Bains, 2010; . For example, catecholamine-mediated excitation of neurons within the PVH requires a glutamatergic component located in or around the PVH (Daftary, Boudaba, & Tasker, 2000; Herman et al., 2003) . Knowing this, some hindbrain catecholamine neurons contain vesicular glutamate transporter 2 (VGluT2) mRNA (Stornetta, Sevigny, & Guyenet, 2002) raising the possibility that these neurons have an intrinsic glutamatergic transmitter component (El Mestikawy, Wall en-Mackenzie, Fortin, Descarries, & Trudeau, 2011; DePuy et al., 2013) . It is also important to note that further afferent regulation derives from the many neuropeptides that co-occur in glutamatergic, GABAergic, and catecholaminergic inputs. These include NPY, AgRP, a-MSH, GLP-1, CART, PrRP, and PACAP. (L egr adi, Hannibal, & Lechan, 1998; Li et al., 2000; Matsumoto et al., 2000; Khan, Walker, Dominguez, & Watts, 2013; Yoon, Lee, & Lee, 2013; Zheng, Stornetta, Agassandian, & Rinaman, 2015) .
Our goal here is to elaborate how pre-synaptic terminals in the PVHmpd contribute to the functional anatomy of the pre-motor control network that controls neuroendocrine, and particularly CRH, neuronal activity (Herman et al., 2002 (Herman et al., , 2003 Watts, 2005; . To do this we analyze the distribution and neurochemical nature of synaptophysin-containing pre-synaptic terminals in the rat and mouse PVHmpd. Synaptophysin is a ubiquitous, vesicular membranebound protein (Wiedenmann & Franke 1985) and its presence indicates pre-synaptic terminals (Masliah, Terry, Alford, & DeTeresa, 1990; Thiel, 1993; Flak et al., 2009; Kwon & Chapman, 2011; Chavan et al., 2015) .
Our analyses are limited to markers of glutamate neurotransmission (vesicular glutamate transporters 2 and 3; VGlut2, VGluT3), GABA neurotransmission (vesicular GABA transporter; VGAT), the catecholamines (PMNT and DBH), neuropeptide Y (NPY) and, agouti-related peptide (AgRP).
We used double-and triple-label immunohistochemistry (IHC) followed by high resolution 3-dimensional (3D) image analyses of confocal photomicrographs to determine three parameters: the relative abundance of different pre-synaptic terminal phenotypes within the PVHmpd of unstressed rats and mice; any co-occurrence of neurochemical markers within these terminals; and in mice, their appositions with CRH neurons.
| M A TER I A LS A N D M ETH OD S

| Animals
Nine adult male Sprague Dawley rats (300g body weight) (Harlan) were housed two-or three-to-a-cage in a climate-controlled room (20-228C), on a 12 hr light/dark cycle (lights on 0600h) with unrestricted access to food and water. Animals were acclimated and handled daily for at least five days before any procedures. The brains of six adult female Crh-IRES-Cre;Ai14 mice (Wamsteeker Cusulin, F€ uzesi, Watts, & Bains, 2013) were shipped from the University of Calgary and immediately stored at 2808C until further processing. All procedures were approved by the local Institutional Care and Use Committees.
| Perfusion and sectioning
Rats were transcardially perfused with 100mL of cold 0.9% saline, followed by 500mL of cold 4% paraformaldehyde in a sodium borate solution (pH 9.5). Brains were removed and post-fixed overnight at 48C in a solution of the same fixative, with the addition of 12% (w/v) sucrose.
Brains were frozen in hexanes cooled by dry ice before being sectioned coronally at 20lm through the rostrocaudal extent of the PVH using a sliding microtome, then stored in a cryoprotectant solution (50% 0.05M sodium-phosphate buffer, 30% ethylene glycol, 20% glycerol) at 2208C until further processing. Seven series were reserved for IHC and one series was reserved for thionin staining to verify cytoarchitecture. Mouse brains were perfused and processed in the same manner but with a lower volume of fixative (Wamsteeker & Bains, 2010; Wamsteeker Cusulin et al., 2013) .
| Immunohistochemistry
Sections were washed in tris-buffered saline (TBS, pH 7.4, six rinses for five minutes each at room temperature (RT)), and allowed to incubate for 2 hr (RT) in a blocking solution of TBS containing 2% (v/v) normal donkey serum (Chemicon, Temecula, CA, S30-100ML) and 0.03% (v/v) Triton X-100 (Sigma Aldrich, 9002-93-1). Sections were incubated in the same blocking solution containing various combinations of primary antibodies (Table 1) for 72 hr at 48C. Sections were again washed in TBS and incubated in a solution of appropriate and corresponding species-sourced secondary antibodies (Table 2 ) overnight at 48C. The sections were washed a final time as before then mounted onto Superfrost slides and allowed to air dry in the dark at RT. Once dry the slides Western blot analysis recognizes a band of 70kDa in rat tissue (Bruinstroop et al., 2012) . Additionally, immunolabeling is abolished following preadsorption with the immunogen (Rinaman, 2001 ).
| Rabbit anti-DBH antibody
This antibody was characterized using Western blot of purified DBH, 
| Sheep anti-neuropeptide Y (NPY) antibody
Specificity was determined by the manufacturers through the use of radioimmunoassay, and immunolabeling was completely abolished following preabsorption with the immunogen. The antibody showed 36% cross-reactivity with Peptide YY, though through the use of NPY knockout mice there is no immunolabeling by the antibody in either the forebrain or brainstem, indicating that there is no substantial cross-labeling with Peptide YY .
| Rabbit anti-phenylethanolamine N-methyltransferase (PNMT) antibody
This antibody only labels the adrenergic cell groups (C1-3) of the hindbrain (Bohn, Dreyfus, Friedman, & Markey, 1987; Rosin, Chang, & Guyenet, 2006) . Additional specificity controls were established through Western blot analysis, where the antibody was shown to recognize a single 35kDa band, while labeling no bands from the liver, spleen, or cerebral cortex (Bohn et al., 1987) . 
| Rabbit anti-VGAT antibody
Western blot analysis show a single 60kDa band in rat brain tissue (Chaudhry et al., 1998) . Additionally, Western blot analyses of brain tissue from VGAT-/-knockout mice is completely devoid of this band (Martens et al., 2008) .
| Guinea pig anti-VGluT2 antibody
The manufacturer's Western blot analysis shows a single band at 52kD. Additionally, when the tissue was incubated with the immunogen, immunolabeling was abolished (Bochorishvili, Stornetta, Coates, & Guyenet, 2012) .
| Guinea pig anti-VGluT3 antibody
Western blot analysis recognizes a single 65kDa band (from the man- 
| Confocal microscopy
Images were captured using a Zeiss 700 Laser Scanning Confocal
Microscope equipped with a Zeiss AxioImager Z1 camera (Carl Zeiss MicroImaging, Inc., Thorwood, NY), using a 40x (numerical aperture 1.3) oil-corrected objective. An optical zoom of 1.6 was applied using the Zeiss Zen software (Zeiss Zen Black) to result in an image magnified to 643. Images were taken using a unidirectional line scan at 1024 3 1024 pixels captured on an 8 bit gray scale. Each pixel was scanned twice and the result was averaged to reduce optical noise.
On this scale the intensity of a pixel is given a value ranging from 0 (black, no fluorescent labeling) to 255 (white, maximal fluorescent labeling). To ensure we captured the full range of fluorescent intensities, as well as to ensure proper alignment of each optical channel, images were first taken using fluorescent beads (15lm in diameter) (FocalCheck Fluorescence Microscope Test Slide #1, Invitrogen, F36909) expressing fluorophores for each laser line used. The lower limit (a black value of 0) was set by blocking the light path completely and verifying that all pixels registered a value of 0. This was adjusted using the Offset function in the Zeiss Zen software, and was done for each fluorophore channel used. To set the upper limit, or saturated value of 255, we used the fluorescent beads.
For each fluorophore channel the image was adjusted using the Master Gain function to ensure that all labeled pixels registered a value of 255, as the concentrated fluorescent dye in the beads is presumably more intense than labeling in physiological tissue. By ensuring that the camera is capable of capturing every possible value assigned to a pixel, we can analyze and compare different levels of fluorophore intensity.
The Airy unit was set to 1.0 for all laser channels, allowing for an optimal signal to noise ratio based on the properties of each laser channel. Appropriate emission filters were applied to prevent bleedthrough between optical channels. 3D images were constructed by taking images of planes (1 lm) through the Z axis, with a frequency of 0.4 lm, throughout the entire depth of the tissue section. Images were analyzed using Volocity software (PerkinElmer, version 6.3, Waltham, MA), operating on a MacBook Pro (Apple, Inc.).
The images for the rat PVHmpd were captured from sections corresponding to Levels 25-26 of the Swanson Rat Brain Atlas (Swanson, 2004) . Images of the mouse PVHmpd corresponded to Levels 61-62 of the Allen Reference Atlas (Dong, 2007; Biag et al., 2011) . Anatomical regions of interest were identified using adjacent Nissl-stained sections ( Figure 1 ).
| Image adjustments
A number of image corrections were employed before analysis. Images of the fluorescent beads were analyzed to ensure that all channels were properly aligned. At the scale of pre-synaptic terminals, any misalignment of images caused by light properties, external vibrations, or other sources of interference has serious consequences on accurate analysis. If all labeled fluorophores did not align in each dimension (X, Y, and Z), the alignment was corrected using the Registration Correction feature in Volocity. Subsequent experimental images were corrected using the same settings. To reduce optical aberrations caused by diffraction, particularly along the Z axis, image deconvolution was achieved through the Iterative Restoration feature using the Measured Point Spread Function in Volocity. One caveat to these methods is that our ability to resolve smaller appositions in the Z-axis is reduced compared to the X-Y axes because of spherical aberration. However, because our results are reported as relative comparisons and these differences are equally distributed across all samples, we believe they are adequately controlled. defined neurons within them is somewhat more homogenous in the rat than the mouse (Simmons & Swanson, 2009; Biag et al., 2011) . In the rat most neuroendocrine CRH neurons are clustered in the PVHmpd between levels 25 and 26 (Swanson, 2004) , where they are by far the most predominant peptide phenotype (Simmons & Swanson, 2009; . We therefore limited our analyses to these two levels of the rat PVHmpd (Figure 1 ).
The distinct compartmental organization of the rat PVH is much less apparent in the mouse where the different chemical phenotypes are distributed more heterogeneously (Biag et al., 2011) . Most CRH neurons are located between levels 61-62 of the Allen mouse brain atlas (Dong, 2007) . To analyze these neurons in the mouse we used a transgenic line, Crh-IRES-Cre;Ai14, wherein all CRH neurons express the tdTomato fluorophore throughout their entirety (Wamsteeker Cusulin et al., 2013) (Figure 1 ). This endogenous labeling enables identification of pre-synaptic terminals that are immediately apposed to CRH neurons.
2.7.2 | Fluorophore co-occurrence Dunn, Kamocka, and McDonald, (2011) have noted the importance of two components when assessing the colocalization of structures labeled with different fluorescent labels: co-occurrence, where two or more markers label the same physical structure; and correlation, wherein the fluorescent intensities of those co-occurring labels vary in a significantly correlated manner.
To determine the co-occurrence of two labels, the total number of each type of fluorescently-labeled structure was quantified within a defined region of interest in the PVHmpd. We then quantified those structures that were double-and/or triple-labeled, using Volocity software to build a protocol that identified each population of structures based on fluorophore expression. Thresholds were set to reduce aberrant signaling in both the volume and fluorescent-intensity parameters.
To be considered a labeled structure a minimum volume threshold of 0.5 lm 3 was applied, along with a maximum threshold of 5lm 3 for presynaptic terminals. Thresholds for volume were determined through comparisons with previously published methods (Bouyer & Simerly, 2013) . Furthermore, a minimum threshold of two standard deviations above the mean background fluorescent intensity was applied. Soma were defined as appropriately-labeled structures with a volume 100
, but 500 lm 3 (mouse) and quantified through the Volocity software throughout the depth of the tissue. These values were determined to be the most appropriate thresholds to allow for the identification of single soma excluding axons and dendrites.
The Intersect function in Volocity was applied to determine the co-occurrence of overlapping populations, wherein structures containing both of the indicated fluorophores were counted as a separate population. To find those structures containing DBH but not PNMT the Intersect function was applied followed by the Exclude Touching function. This prohibited the quantification of DBH-labeled structures that also contained PNMT, leaving only single-labeled structures in the analysis. by the total number of appositions from the entire image for each terminal marker. The residual structures were designated nonsomatic.
We were unable to identify DBH-immunoreactive (ir) appositions to nonsomatic regions because of DBH and synaptophysin primary antibody species incompatibility. However, we used the voxel-to-voxel ('touching structures') approach described by Bouyer and Simerly (2013) to identify DBH-ir appositions with CRH neuronal soma. 
| Excel analysis
| Validation controls for the methods of assessing co-occurrence
We performed two sets of controls for the rat PVH to validate the cooccurrence methods.
| Theoretical controls
Sections containing the rat PVHmpd were co-labeled using two different antibodies against DBH: a mouse anti-DBH antibody and a rabbit anti-DBH antibody. Because these antibodies should theoretically identify the same structures, there should be no significant difference between the percent of mouse anti-DBH-labeled structures that express rabbit anti-DBH and the percent of rabbit anti-DBH-labeled structures that express mouse DBH. 
| Statistics
Significant differences between group means were determined using TdTomato-labeled CRH soma are visible in the mouse panels. Equivalent images are not shown for VGAT or VGluT3. Please see Figure 2 for more information about the general organization of the confocal image panels. Panels (i-l) show higher magnification images of the area indicated by the dashed line square in (e). Scale bar in (a) and (e) indicates 20lm for panels (a-h). Scale bar in (i) indicates 100mm. All VGluT2 and VGAT occurs in rat and mouse (female) pre-synaptic terminals (m, n), but not not all VGluT3 occurs in rat pre-synaptic terminals (m, n). There are significantly more VGAT presynaptic terminals than either Glu transporters, and significantly more VGluT2 than VGluT3 terminals (n). 
| Technical controls
'Adrenergic' structures contain both DBH and PNMT, while 'noradrenergic' structures only contain DBH (Goldstein, Fuxe, & H€ okfelt, 1972; Swanson et al., 1981) . When we double-labeled sections with DBH and PNMT antibodies (Figure 2f -i) we found virtually all PNMT-labeled structures contain DBH (Figure 2j ), but significantly fewer DBH-labeled structures contain PNMT (Figure 2j ). These findings validate our ability to use these antibodies to differentiate between structures with these two different catecholaminergic phenotypes. 
| Vesicular glutamate and GABA transporter distributions in the rat PVH region and their organization within terminal appositions
| VGluT2 and VGAT co-occur in a population of terminals in the PVHmpd
When we analyzed the co-occurrence of VGluT2 and VGAT in the rat PVHmpd ( Figure 5) we found approximately 8% of synaptophysinlabeled pre-synaptic terminals contained both vesicular transporters (Figure 5e ). The number of these double-labeled pre-synaptic terminals was considerably less than the pre-synaptic terminals single-labeled for either VGluT2 or VGAT only (Figure 5e ). VGluT2 and VGAT cooccurrence could not be assessed in the mouse because of species incompatibility with the appropriate antibodies. reports showing that PNMT-containing afferents preferentially innervate the parvicellular parts of the PVH that mediate neuroendocrine responses (Swanson et al., 1981; Cunningham et al., 1990) .
| Catecholaminergic axon terminals express VGluT2 in the PVHmpd of the rat and the mouse
In the rat PVHmpd, approximately 25% of all VGluT2-containing presynaptic terminals also expressed catecholaminergic markers ( Figure   7a -h). However, Figure 7i shows that there was a much higher incidence of VGluT2 co-occurrence in PNMT-containing (21%) than in DBH-only-containing terminals (4%).
We also analyzed the number of pre-synaptic terminals and the co-occurrence of VGluT2 and DBH in the mouse (Figure 7j-m) .
Because the PNMT antibody did not produce specific staining in mouse brain sections, we were unable to differentiate PNMT-ir structures from DBH-only-ir structures. Like the rat PVHmpd, there were significantly more VGluT2-containing pre-synaptic terminals than catecholaminergic pre-synaptic terminals in the female mouse PVHmpd ( Figure   7n ). VGluT2 and DBH co-occur in the mouse, but there are significantly fewer double-labeled pre-synaptic terminals than either VGluT2-only or catecholaminergic-only pre-synaptic terminals (Figure 7n ).
3.6 | Catecholamines and NPY co-occur in axon terminals in the PVHmpd of the rat Figure 8 shows that almost two thirds of the NPY-ir structures cooccur with either DBH or PNMT or both, while the remaining third cooccurs with AgRP. Furthermore, almost all of the structures labeled with AgRP also contained NPY.
| Appositions to CRH neurons in the mouse PVHmpd
There were large numbers of synaptophysin-labeled axon terminals in the mouse PVHmpd (Figure 9a-c, m) . We found approximately twice the number of somatic VGAT-containing appositions (Figure 9d -f, n) than either VGluT2- (Figure 9g -i, n) or DBH-containing (Figure 9j-l, n) appositions.
We found that approximately 90% of synaptophysin-, VGluT2-, and VGAT-containing appositions were with non-somatic regions rather than somatic regions (Figure 9o ). Although we could not account for the cellular locations of all non-somatic appositions, many VGAT terminals were clearly apposed to what appeared to be dendrites of CRH neurons (Figure 10 ). (Bai et al., 1985; Sawchenko et al., 1985; F€ uzesi, Wittmann, Liposits, Lechan, & Fekete, 2007) , with the remainder originating from other sources, for example the arcuate and dorsomedial nuclei of the hypothalamus (Bai et al., 1985; F€ uzesi et al., 2007; Lee et al., 2013) . The NPY innervation originating from the arcuate nucleus also contains AgRP (Hahn, Breininger, Baskin, & Schwartz, 1998) and is GABAergic (Tong, Ye, Jones, Elmquist, & Lowell, 2008) . Figure 11 shows that presynaptic terminals containing VGluT2 and VGAT account for at least 85% of the total number of synaptophysinlabeled terminals in the rat and mouse PVHmpd. Of these, just over half contain VGAT. These numbers agree with previous electron microscopic (EM) surveys of GABAergic synapses (Decavel & van den Pol, 1990; Mikl os & Kov acs, 2002 .
| Glutamate/GABA
GABAergic terminals make direct contact with CRH neurons and use GABA A receptor signaling to exert strong inhibitory influence over them and the HPA axis (Cole & Sawchenko, 2002; Mikl os & Kov acs, 2002 Bali & Kov acs, 2003; Cullinan, 2000; Cullinan, Ziegler, & Herman, 2008) . We found twice as many VGAT-containing terminals apposed to CRH neuronal soma than VGluT2-or DBH-containing terminals to help enable this strong inhibitory control.
The second largest group of synaptophysin-labeled terminals contain VGluT2 (Figure 11 ). The fact that afferent activation elicits glutamatergic excitatory post-synaptic potentials in parvicellular PVH neurons (Wuarin & Dudek, 1991; Daftary et al., 2000) is consistent with the likelihood that VGluT2 expressed in PVHmpd terminals is associated with pre-synaptic glutamate release . The lack of suitable markers has made EM examinations of glutamatergic synapses in the PVHmpd more challenging than for GABA, but the consensus is that glutamate provides a significant innervation to the PVH including CRH neurons (van den Pol, Wuarin, & Dudek, 1990; Wittmann et al., 2005) . Our results are consistent with these findings.
To understand how afferent networks control neuroendocrine neurons it is important to know on which parts of these neurons particular inputs form synapses. Electron microscopy (EM) provides the most detailed level of analysis. These EM studies consistently indicate that the great majority of PVH pre-synaptic terminals are found on dendrites (Decavel & van den Pol, 1990) . Using a CRH reporter mouse (Wamsteeker Cusulin et al., 2013) we found only about 10% of all synaptophysin-defined terminals apposed to CRH neuronal soma.
These findings are consistent with previous EM distribution analyses of somatic versus nonsomatic synapses in the rat medial parvicellular PVH (Decavel & van den Pol, 1990; Mikl os & Kov acs, 2012) . Our percentages are somewhat higher than those reported by Mikl os and Kov acs (72%) (2012) perhaps because they used colchicine to help visualize CRH neurons. Colchicine can dramatically alter CRH neuronal morphology, including somatic area, and dendritic spine number and density (Rho & Swanson, 1989) . We found that somatically located GABAergic terminals are significantly more abundant than glutamatergic and DBHcontaining terminals. The remaining synaptophysin-defined terminals are most likely axo-dendritic, but with no apparent differences between the proportions of GABAergic and glutamatergic terminals.
These results are again consistent with GABAergic inhibition being the predominant control component for these neurons.
Although we found some VGluT3/synaptophysin co-occurrence that may correspond to synaptic glutamate release, it was much less frequent than with VGluT2 or VGAT, meaning that VGluT3 has a more widespread non-terminal distribution within PVHmpd neurons than the other two transporters. The apparent expression of VGluT3 in the soma of magnocellular neurons is consistent with this view. VGluT3 is found in pre-synaptic terminals, cell bodies, and dendrites of neurons not traditionally considered glutamatergic, particularly serotonergic and cholinergic neurons (Fremeau et al., 2002; Gras et al., 2002; Herzog et al., 2004; Kljakic, Janickova, Prado, & Prado, 2017; Somogyi et al., 2004; Commons, 2009) . Therefore VGluT3/synaptophysin cooccurrence may be in serotonergic or possibly cholinergic terminals rather than glutamatergic (Figure 11 ).
| VGluT2 and VGAT co-occurrence
We found a relatively small number of pre-synaptic terminals containing both VGluT2 and VGAT. Although these populations have generally been considered mutually exclusive it is evident that this is not always the case (Boudaba et al., 1996; Ottem, Godwin, Krishnan, & Petersen, 2004; Zander et al., 2010) . While the primary function of vesicular transporters is to package fast-acting neurotransmitters into synaptic vesicles (McIntire, Reimer, Schuske, Edwards, & Jorgensen, 1997; Chaudhry et al., 1998; Fremeau et al., 2002; Herzog et al., 2001) , the presence of the VGluTs does not unambiguously mark synaptically releasable glutamate. When VGluTs are found in the same terminals as other transporters, including VGAT, they can augment the packaging ability of the principal transmitter transporter, a process called vesicular synergy (El Mestikawy et al., 2011; Mu€nster-Wandowski et al., 2016) .
Additionally, VGluTs may be involved in the transport of inorganic phosphate into vesicles, independent of glutamate transport (Ni, Rosteck, Nadi, & Paul, 1994; Aihara et al., 2000; Juge, Yoshida, Yatsushiro, Omote, & Moriyama, 2006) . Collectively these results mean that
PVHmpd pre-synaptic terminals with VGluT2/VGAT co-occurrence are more likely GABAergic than glutamatergic (Figure 11 ).
| Catecholamines
The locations of catecholaminergic neurons have traditionally been defined by the expression of their biosynthetic enzymes: dopaminergic (A9 etc. groups; TH, but not DBH or PNMT); noradrenergic (A1-A8 groups; TH and DBH, but not PNMT); and adrenergic (C1-C3 groups;
all three enzymes). Using this nomenclature, virtually all the catecholaminergic innervation of the PVH originates from two medullary locations: the ventrolateral medulla (VLM) (A1, A1/C1, and C1) and the nucleus of the solitary tract (NTS) (A2 and C2), although some periventricular noradrenergic inputs come from the locus coeruleus (A6) (Cunningham & Sawchenko, 1988) . The A1 group primarily innervates magnocellular neurons; the A2 group innervates both parvi-and magnocellular parts (Swanson et al., 1981; Cunningham & Sawchenko, 1988) ; while the C1 and C2 groups target its parvicellular parts (Swanson et al., 1981; Cunningham et al., 1990) . VGluT2 mRNA is found in the majority of PNMT-expressing cell groups, as well as in some A2 neurons, but its expression appears to be most widespread in C1 neurons (Stornetta et al., 2002 (Tucker, Saper, Ruggiero, & Reis, 1987; Guyenet et al., 2013) . These C1 neurons project heavily to the PVHmpd (Swanson et al., 1981; Cunningham et al., 1990) . They make asymmetric synapses with their targets (Liposits et al., 1986a,b) , which are structurally similar to the glutamatergic synapses made by C1 neurons in the hindbrain (Sheng & Kim, 2011; DePuy et al., 2013) . We now provide the first evidence that a significant number of DBH/PNMT-containing axon terminals in the PVHmpd also contain VGluT2, meaning that-like caudally directed C1 neurons-glutamate is probably their primary ionotropic transmitter. Previous reports suggest that catecholaminergic neurons engage glutamatergic interneurons to alter parvicellular neuronal function in the PVH (Daftary et al., 2000; Herman et al., 2003) , but our results now indicate that at least a subset of these catecholaminergic inputs can themselves release glutamate.
Are catecholamines released by the terminals of C1 or C2 neurons projecting into the PVH? There is a notable lack of direct evidence for epinephrine and/or norepinephrine release from the axon terminals, dendrites, or other parts of caudally projecting C1 neurons . The fact that PNMT in the hindbrain and spinal cord does not reliably indicate the presence of releasable epinephrine is consistent with this view (Sved, 1989) . These neurons synthesize but do not store epinephrine in vesicles, most likely because elevated levels of monoamine oxidase quickly degrades nonvesicular epinephrine (Sved, 1989 (Sved, , 1990 . We find approximately five times as many PNMTcontaining pre-synaptic terminals in the PVHmpd as those containing only DBH. Conventionally this should mean that these neurons will release epinephrine and norepinephrine, respectively. Therefore, it is very surprising that epinephrine release in the PVH has never been detected by microdialysis or fast-scan cyclic voltammetry after various challenges (Pacak, Palkovits, Kopin, & Goldstein, 1995; Pacak et al., 1998; Pacak & Palkovits, 2001; Gerth & Roitman, 2016) . The difference between C1 neurons projecting to the hindbrain/spinal cord and those that project to the hypothalamus may result from how hypothalamic monoamine oxidase acts on epinephrine and norepinephrine, the different cellular locations of DBH (vesicular) and PNMT (cytoplasmic) (Sved, 1990) , and the reported absence of a membrane transporter in most C1 neurons (Lorang, Amara, & Simerly, 1994; Comer, Qi, Christie, Gibbons, & Lipski, 1998) .
A lack of measureable epinephrine release in the PVH has two interpretational consequences. First, DBH-and PNMT-containing terminals in the PVH both release norepinephrine, and therefore both should be considered noradrenergic (Figure 11) . Second, the presence or absence of PNMT may not coincide with different releasable catecholamines. Instead it identifies two anatomically distinct neuronal populations with different neuropeptides, afferents, and functional consequences for post-synaptic PVH neurons. For example, PNMTcontaining neurons are preferentially recruited by 2DG-induced glucoprivation (Ritter, Llewellyn-Smith, & Dinh, 1998) , and particularly by insulin-induced hypoglycemia, which activates more neurons in the C1 region than in A1, A2, and C2 (Jokiaho, Donovan, & Watts, 2014) .
FIG URE 11
Pre-Synaptic Terminal Diversity in the Rat PVHmpd. Figure 11 summarizes two sets of relationships in pre-synaptic terminals identified in the rat PVHmpd in the absence of stressors: 1) Marker. The height of each box approximates the proportion of that marker to the total number of synaptophysin-labeled pre-synaptic terminals. Overlapping boxes indicate co-occurrence between two markers. While we did not investigate the co-occurrence of VGAT with NPY, the majority of NPY innervation co-occurs with catecholaminergic (and particularly PNMT-containing afferents. The remainder originated from hypothalamic sources (Bai et al., 1985; Sawchenko et al., 1985; F€ uzesi et al., 2007) . NPY originating from the arcuate nucleus co-occurs with AgRP, the majority of which is GABAergic (Tong et al., 2008) . While we did not investigate serotonergic or cholinergic inputs, evidence indicates that serotonergic inputs originate from hindbrain raphe neurons that contain VGluT3 (Gras et al., 2002; Herzog et al., 2004) . 2) Type The presumed major signaling molecule. AgRP 5 agouti-related peptide; DBH 5 dopamine b-hydroxylase; aMSH, NPY 5 neuropeptide Y; PNMT 5 phenylethanolamine N-methyltransferase; VGAT 5 vesicular GABA transporter; VGlut2 5 vesicular glutamate transporter 2; VGlut3 5 vesicular glutamate transporter 3 JOHNSON ET AL.
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The post-synaptic effects of norepinephrine on PVH parvicellular neurons are varied and complex. Applying norepinephrine to hypothalamic slices containing the PVH increases the firing rates of most parvicellular neurons using ionotropic glutamate receptor-, a1
adrenoreceptor-, and mitogen-activated protein kinase kinase (MEK)-dependent mechanisms (Daftary et al., 2000; Khan et al., 2011) . Conversely, a minority of neurons are inhibited by norepinephrine using b-adrenoreceptor-dependent mechanism (Daftary et al., 2000) . Our structural results now show that at least part of the glutamatergic component in this effect likely originates directly from mostly C1-originating and PNMT-containing terminals in the PVHmpd.
While the relationship between the mechanisms used by norepinephrine to alter parvicellular neuron excitation and the various neuronal components in the PVHmpd are unknown, one key synaptic mechanism is worth noting. Norepinephrine can regulate GABA synaptic plasticity using a mGluR1-dependent metaplastic effect on the ability of GABA synapses to express LTP (Inoue et al., 2013) . This occurs because the norepinephrine released by a stressor into the PVHmpd increases post-synaptic GABA A receptor membrane insertion, thereby increasing GABA LTP, and consequently post-synaptic responsiveness to subsequent stressors (Bains et al., 2015) .
| C ONC LUSI ON S
Our results reveal complex relationships between glutamate, GABA, and norepinephrine in pre-synaptic terminals of the neuroendocrine pre-motor networks in the PVHmpd. Complexity is further increased when we consider the other co-occurring peptides and other signaling systems that are known to be present in PVHmpd afferents. An important functional consideration is that the inability of other studies to detect epinephrine release in the PVH suggests that all catecholamine terminals in the PVHmpd, including those containing PNMT, release norepinephrine. For CRH neurons, the dynamic regulation of their presynaptic signaling molecules should significantly increase synaptic flexibility in a way that is well-placed to mediate adaptive CRH neuronal responses to different glucocorticoid environments and stressor exposures (Watts, 2005) . Further investigation is needed to determine how and when this dynamic regulation is mediated-including for example, whether the various signaling molecules are arranged in a co-release or a co-transmission configuration (Vaaga, Borisovska, & Westbrook, 2014) -and under what circumstances the various signals are released.
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